Business
What Goldman Sachs is saying about the CSL (ASX:CSL) share price after its R&D update
Image source: Getty Images
Last week was a reasonably disappointing one for the CSL Limited (ASX: CSL) share price.
Despite releasing its research and development (R&D) update for 2021, the biotherapeutics company’s shares ended the period with a weekly decline of 0.5%.
What was the reaction…
Continue Reading
-
Business16 hours agoWhy did this ASX 200 healthcare stock crash 14% yesterday?
-
General24 hours agoRussia launches hundreds of drones and missiles against Ukraine in fresh attack
-
Business15 hours agoHere’s what analysts expect for the BHP share price in the coming year
-
Business18 hours agoOwn Xero shares? Here are 3 key takeaways from its AGM